Home
In FY2025, Rilemo invested its resources in building the technological and scientific foundation of the company. The year was characterized by intensive R&D activity, patent development, and team formation, with the balance sheet reflecting the assets created rather than revenues generated. The company enters 2026 debt-free, well-capitalized, and with a validated product pipeline.
Where the money went
Total operating expenditure for the year was €154,160, predominantly directed toward value-creating activities:
- Personnel (€65,199), ****for a team that is primarily R&D-oriented, as confirmed by the volume of internal work capitalized during the year (€76,657 in intangible assets under development).
- Additional services (€48,547), covering technical consulting, IP management, and early commercial activities.
- R&D materials and equipment purchases (€31,299).
What was built
The investment translated directly into balance sheet assets. Total assets at year-end stand at €520,875:
- Intangible assets (€107,401), that includes €78,057 of R&D and software in progress, plus registered patents and licenses (€27,377). See Intellectual Property for the full IP portfolio.
- Tangible assets (€51,961), that includes lab equipment and hardware for product development.
- Cash and bank deposits (€324,602), reflecting the shareholder contributions received during the year, net of operating expenditure.
Financial structure
The company's balance sheet is clean and investor-ready:
- Total equity (€475,910), primarily derived from the €512,000 in shareholder contributions already recorded as future capital increase. See Funding History and Cap Table.
- Zero financial debt.
- Net loss for the year (€46,090), entirely attributable to the pre-revenue investment phase, consistent with the stage of development.